The DOI matches its Crossref record; 115 of the 121 references it cites were found in a registry or an index.
Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus
Open accessAbstract
BACKGROUND: In type 2 diabetes mellitus there is a progressive loss of beta-cell function. One new approach yielding promising results is the use of the orally active dipeptidyl peptidase-4 (DPP-4) inhibitors like sitagliptin and vildagliptin. OBJECTIVES: To assess the effects of dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. SEARCH STRATEGY: Studies were obtained from computerised searches of MEDLINE, EMBASE and The Cochrane Library. SELECTION CRITERIA: Studies were included if they were randomised controlled trials in adult people with type 2 diabetes mellitus and had a trial duration of at least 12 weeks. DATA COLLECTION AND ANALYSIS: Two authors independently assessed risk of bias and extracted data. Pooling of studies was performed by means of fixed-effect meta-analysis. MAIN RESULTS: Twenty-five studies of good quality were identified, 11 trials evaluated sitagliptin and 14 trials vildagliptin treatment. Altogether, 6743 patients were randomised in sitagliptin and 6121 patients in vildagliptin studies, respectively. Sitagliptin and vildagliptin studies ranged from 12 to 52 weeks duration. No data were published on mortality, diabetic complications, costs of treatment and health-related quality of life. Sitagliptin and vildagliptin therapy in comparison with placebo resulted in an HbA1c reduction of approximately 0.7% and 0.6%, respectively. Data on comparisons with active comparators were limited but indicated no improved metabolic control following DPP-4 intervention in contrast to other hypoglycaemic agents. Sitagliptin and vildagliptin therapy did not result in weight gain but weight loss was more pronounced following placebo interventions. No definite conclusions could be drawn from published data on sitagliptin and vildagliptin effects on measurements of beta-cell function. Overall, sitagliptin and vildagliptin were well tolerated, no severe hypoglycaemia was reported in patients taking sitagliptin or vildagliptin. All-cause infections increased significantly after sitagliptin treatment but did not reach statistical significance following vildagliptin therapy. All published randomised controlled trials of at least 12 weeks treatment with sitagliptin and vildagliptin only reported routine laboratory safety measurements AUTHORS' CONCLUSIONS: DPP-4 inhibitors have some theoretical advantages over existing therapies with oral antidiabetic compounds but should currently be restricted to individual patients. Long-term data especially on cardiovascular outcomes and safety are urgently needed before widespread use of these new agents. More information on the benefit-risk ratio of DPP-4 inhibitor treatment is necessary especially analysing adverse effects on parameters of immune function. Also, long-term data are needed investigating patient-oriented parameters like health-related quality of life, diabetic complications and all-cause mortality.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The potential for this class of compounds to interfere with immune function is of concern; an increase in upper respiratory infections has been reported (34).”
From Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy (2009) · cites this paper as [34]
Citations
Cites
2 retracted
Metformin monotherapy for type 2 diabetes mellitus
Sáenz, A., Fernandez-Esteban, I., Mataix, A. L., Segura, M. A., Figuls, M. R. I., & Moher, D. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002966.pub3 · Cited by 310
RetractedDietary advice for the prevention of type 2 diabetes mellitus in adults
Nield, L., Summerbell, C., Hooper, L., Whittaker, V., & Moore, H. J. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005102.pub2 · Cited by 92
RetractedMeasuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
A Coefficient of Agreement for Nominal Scales
Cohen, J. (1960) · Educational and Psychological Measurement · doi:10.1177/001316446002000104 · Cited by 42,398
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,369
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,325
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Research works printed but not linked: 7
- Mimori, 2006, Vildagliptin improves glucose control as evidenced by HbA1c after 12 weeks in Japanese patients with type 2 diabetes, Diabetes, 55(suppl 1), A125
- Nonaka, 2006, Twelve-week efficacy and tolerability of sitagliptin, a dipeptidyl peptidase-IV inhibitor, in Japanese patients with T2DM, Diabetes, 55(suppl 1), A129
- Canadian Agency for Drugs and Technologies in Health, 2006, Vildagliptin (Structured abstract), Ottawa : Canadian Agency for Drugs and Technologies in Health
- Drucker, 2007, Sitagliptin, Nature Reviews, Drug Discovery., 109
- Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005] In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd
- Kahn, 1997, The pathophysiology of type II (noninsulindependent) diabetes mellitus: implications for treatment
- Schlesselman, 2006, Vildagliptin: A dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes, Formulary, 41, 494
Cited by
Sorted by citations
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
“The potential for this class of compounds to interfere with immune function is of concern; an increase in upper respiratory infections has been reported (34).”
BackgroundDeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347
“6%, respectively, in comparison with placebo (73).”
Trends in insulin resistance: insights into mechanisms and therapeutic strategy
Li, M., Chi, X., Wang, Y., Setrerrahmane, S., Xie, W., & Xu, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01073-0 · Cited by 939
Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis
Kumar, A., Arora, A., Sharma, P., Anikhindi, S. A., Bansal, N. K., Singla, V., Khare, S., & Srivastava, A. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.04.044 · Cited by 814
“Two recent meta-analyses had shown that DPP4 inhibitors increased the risk of various infections [42,43] while a third meta-analysis showed that there is no increased risk of infections with DPP4 inhibitors [44].”
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetologia · doi:10.1007/s00125-008-1157-y · Cited by 712
“The potential for this class of compounds to interfere with immune function is of concern; an increase in upper respiratory infections has been reported [34].”
Metformin: An Old But Still the Best Treatment for Type 2 Diabetes
Rojas, L. B. A., & Gomes, M. B. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-6 · Cited by 567
“The mechanism of DPPIV inhibitors is complementary to that of metformin which improves insulin sensitivity and reduces hepatic glucose production, making this combination very useful for achieving adequate glycemic control [39].”
BackgroundDipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative review
Deacon, C. F. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01306.x · Cited by 528
The incretin system and its role in type 2 diabetes mellitus
Holst, J. J., Vilsboll, T., & Deacon, C. F. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.08.012 · Cited by 528
Matching-Adjusted Indirect Comparisons: A New Tool for Timely Comparative Effectiveness Research
Signorovitch, J., Sikirica, V., Erder, M. H., Xie, J., Lü, M., Hodgkins, P., Betts, K. A., & Wu, E. Q. (2012) · Value in Health · doi:10.1016/j.jval.2012.05.004 · Cited by 509
Bennett, W. L., Maruthur, N. M., Singh, S., Segal, J. B., Wilson, L. M., Chatterjee, R., Marinopoulos, S. S., Puhan, M. A., Ranasinghe, P., Block, L., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-9-201105030-00336 · Cited by 609
“However, this assumption may be less valid for the newer medications saxagliptin, sitagliptin, nateglinide, exenatide and liraglutide; evidence from other systematic reviews, such as Cochrane reviews, will be helpful in making conclusions about these agents (38, 39, 51).”
BackgroundKaragiannis, T., Paschos, P., Paletas, K., Matthews, D. R., & Tsapas, A. (2012) · BMJ · doi:10.1136/bmj.e1369 · Cited by 435
Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system
Klemann, C., Wagner, L., Stephan, M., & von Hörsten, S. (2016) · Clinical & Experimental Immunology · doi:10.1111/cei.12781 · Cited by 441
Long-Acting Glucagon-Like Peptide 1 Receptor Agonists
Garber, A. J. (2011) · Diabetes Care · doi:10.2337/dc11-s231 · Cited by 350
“The efficacy and tolerability of the DPP-4 inhibitors have been reviewed elsewhere (16).”
BackgroundPrato, S. D., Barnett, A. H., Huisman, H., Neubacher, D., Woerle, H. J., & Dugi, K. A. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01350.x · Cited by 297
Nauck, M. A. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.002 · Cited by 298
Regulation of Glucose Homeostasis by GLP-1
Nadkarni, P., Chepurny, O. G., & Holz, G. G. (2014) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-800101-1.00002-8 · Cited by 287
Pharmacokinetics of dipeptidylpeptidase‐4 inhibitors
Scheen, A. J. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01212.x · Cited by 281
Khunti, K., Alsifri, S., Aronson, R., Cigrovski Berković, M., Enters‐Weijnen, C., Forsén, T., Galstyan, G., Geelhoed‐Duijvestijn, P., Goldfracht, M., Gydesen, H., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12689 · Cited by 276
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
Ferrannini, E., & DeFronzo, R. A. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv239 · Cited by 265
Williams‐Herman, D., Engel, S. S., Round, E., Johnson, J. R., Golm, G. T., Guo, H., Musser, B. J., Davies, M. J., Kaufman, K. D., & Goldstein, B. J. (2010) · BMC Endocrine Disorders · doi:10.1186/1472-6823-10-7 · Cited by 257
“Prior meta-analyses of published studies of DPP-4 inhibitors (including sitagliptin and vildagliptin) have reported an increased risk for infections overall and for specific infections (nasopharyngitis, upper respiratory tract infection, and urinary tract infection) [9,26,34].”
BackgroundMahapatra, D. K., Asati, V., & Bharti, S. K. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.01.051 · Cited by 260
Edridge, C. L., Dunkley, A. J., Bodicoat, D. H., Rose, T. C., Gray, L. J., Davies, M. J., & Khunti, K. K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126427 · Cited by 230
“Previously published systematic reviews that have considered hypoglycaemic episodes in type 2 diabetes have tended to focus on clinical trials of the safety and efficacy of a particular drug (15, 25-30).”
BackgroundMakrilakis, K. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16152720 · Cited by 233
“An early meta-analysis of incretin based therapies (in which inhibitor data were available only for sitagliptin and vildagliptin), suggested that there was an increased risk of some infections (urinary tract infections with both inhibitors and nasopharyngitis more evident with sitagliptin) and headache (more evident w…”
BackgroundThe selection and use of essential medicines.
Kazembe, P. N., Fannah, J. A., Hoppu, K., Zisovska, E., Pedersen, H., Hill, S., Ondari, C. O., Terlouw, D. J., Mattison, D. R., Zhi-ping, L., et al. (2004) · PubMed · Cited by 215
Pharmacology of Dipeptidyl Peptidase-4 Inhibitors
Baetta, R., & Corsini, A. (2011) · Drugs · doi:10.2165/11591400-000000000-00000 · Cited by 213
“A large body of evidence indicates that DPP-4 inhibitors as a class have a good safety and tolerability profile, with a low incidence of mostly mild-to-moderate adverse events (AEs).([125,127,152-155]) First of all, because of the glucose-dependent nature of their insulinotropic effect, they are associated with very l…”
BackgroundDPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats
Pintana, H., Apaijai, N., Chattipakorn, N., & Chattipakorn, S. C. (2013) · Journal of Endocrinology · doi:10.1530/joe-12-0521 · Cited by 211
“It has been shown that DPP-4 inhibitors improve glycemic control in insulin resistance models and T2DM models (Richter et al. 2008).”
BackgroundVerspohl, E. J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.002 · Cited by 198
Powell, D. R., Smith, M. G., Greer, J., Harris, A. L., Zhao, S., DaCosta, C. M., Mseeh, F., Shadoan, M. K., Sands, A., Zambrowicz, B., et al. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.203364 · Cited by 189
“Increasing GLP-1 activity, either by injecting longacting GLP-1 analogs or by inhibiting dipeptidyl peptidase (DPP) IV–mediated GLP-1 inactivation, is clearly associated with improved glycemic control in patients with T2DM (Richter et al., 2008; Shyangdan et al., 2011).”
BackgroundGuideline for management of postmeal glucose in diabetes
1 (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.08.002 · Cited by 185
Nauck, M. A., Vilsbøll, T., Gallwitz, B., Garber, A. J., & Madsbad, S. (2009) · Diabetes Care · doi:10.2337/dc09-s315 · Cited by 182
“Both display beneficial ef fects on weight compared with other oral antidiabetic drugs (except DPP-4 inhibitors versus metformin), however, more pronounced for the GLP-1 receptor agonists (1,20,43).”
BackgroundInfluentialCardiovascular effects of gliptins
Scheen, A. J. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.183 · Cited by 175
Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation
Waugh, N., Cummins, E., Royle, P., Clar, C., Marien, M., Richter, B., & Philip, S. (2010) · Health Technology Assessment · doi:10.3310/hta14360 · Cited by 178
Self-citationDipeptydil peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials
Monami, M., Iacomelli, I., Marchionni, N., & Mannucci, E. (2009) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2009.03.015 · Cited by 175
“Among other expected adverse events, the previously reported increased incidence of some infections during DPP-4 inhibitor therapy [6,8] is confirmed, with sitagliptin, but not vildagliptin, associated with nasopharyngitis, and with a nonsignificant trend toward an increased risk of urinary tract infections.”
BackgroundGooßen, K., & Gräber, S. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01610.x · Cited by 167
Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors
Golightly, L. K., Drayna, C. C., & McDermott, M. T. (2012) · Clinical Pharmacokinetics · doi:10.1007/bf03261927 · Cited by 163
“Clinical studies, systematic reviews and meta-analyses of type 2 diabetes treatments have shown that incretin therapies with both pharmacological GLP-1 agonists([31-35]) and inhibitors of dipeptidyl peptidase-4 (DPP-4), the enzyme primarily responsible for physiological degradation ofGLP-1, generally are well tolerate…”
Improved glycemic control in mice lacking Sglt1 and Sglt2
Powell, D. R., DaCosta, C. M., Gay, J. P., Ding, Z., Smith, M. G., Greer, J., Doree, D. D., Jeter-Jones, S. L., Mseeh, F., Rodriguez, L. A., et al. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00439.2012 · Cited by 161
DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature
Saini, K., Sharma, S., & Khan, Y. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1130625 · Cited by 185
“6%, respectively, in contrast to placebo (Richter et al., 2008b).”
Guideline Development Group., Bilo, H. J. G., Coentrão, L., Couchoud, C., Covic, A. C., SUTTER, J. D., Drechsler, C., Gnudi, L., Goldsmith, D. J. A., Heaf, J. G., et al. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv100 · Cited by 155
Ligueros‐Saylan, M., Foley, J. E., Schweizer, A., Couturier, A., & Kothny, W. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01214.x · Cited by 145
Neumiller, J. J. (2009) · Journal of the American Pharmacists Association · doi:10.1331/japha.2009.09078 · Cited by 144
Dipeptidylpeptitase-4 Inhibitors (Gliptins)
Scheen, A. J. (2010) · Clinical Pharmacokinetics · doi:10.2165/11532980-000000000-00000 · Cited by 146
Clinical Pharmacokinetics and Pharmacodynamics of Linagliptin
Graefe‐Mody, U., Retlich, S., & Friedrich, C. (2012) · Clinical Pharmacokinetics · doi:10.2165/11630900-000000000-00000 · Cited by 144
“9% achieved with linagliptin are consistent with the effects observed with other DPP-4 inhibitors.([48-50]) Reductions in HbA1c of this magnitude are considered clinically meaningful by regulatory authorities and clinical associations.”
Safety of dipeptidyl peptidase 4 inhibitors: a perspective review
Karagiannis, T., Boura, P., & Τσάπας, Α. (2014) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098614523031 · Cited by 136
McIntosh, B., Cameron, C. G., Singh, S. R., Yu, C., Ahuja, T. K., Welton, N. J., & Dahl, M. (2011) · Europe PMC (PubMed Central) · Cited by 129
The effects of glucagon‐like peptide‐1 on the beta cell
Vilsbøll, T. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01073.x · Cited by 116
The safety and tolerability of GLP‐1 receptor agonists in the treatment of type 2 diabetes: a review
Aroda, V. R., & Ratner, R. E. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1202 · Cited by 112
“The safety and tolerability profile of DPP-4 inhibitors are reviewed elsewhere [3].”
BackgroundHaidinger, M., Werzowa, J., Hecking, M., Antlanger, M., Stemer, G., Pleiner, J., Kopecky, C., Kovarik, J. J., Döller, D., Pacini, G., et al. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12518 · Cited by 110
“Dipeptidyl peptidase-4 (DPP-4) inhibitors belong to a new class of antidiabetic drugs that stabilize the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide, resulting in improvedmetabolic control and reduction of postprandial hyperglycemia (21).”
BackgroundRehman, M. B., Tudrej, B. V., Soustre, J., Buisson, M., Archambault, P., Pouchain, D., Vaillant-Roussel, H., Gueyffier, F., Faillie, J., Pérault-Pochat, M.-C., et al. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.09.005 · Cited by 105
Rosiglitazone for type 2 diabetes mellitus
Richter, B., Bandeira-Echtler, E., Bergerhoff, K., Clar, C., & Ebrahim, S. H. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006063.pub2 · Cited by 106
Self-citationHe, J., Chen, L.-X., & Li, H. (2019) · Fitoterapia · doi:10.1016/j.fitote.2019.02.033 · Cited by 102
Novel Pharmacological Approaches to the Treatment of Type 2 Diabetes
Verspohl, E. J. (2012) · Pharmacological Reviews · doi:10.1124/pr.110.003319 · Cited by 103
“…to have contradictory effects: that is, increasing and inhibiting immune responses (reviewed by Hildebrandt, 2004) and long-term safety based on effects on CD26 remains unknown (Richter et al., 2008a) except for a nonspecific increase of infections after sitagliptin therapy (Richter et al., 2008b).”
BackgroundInterventions for latent autoimmune diabetes (LADA) in adults
Brophy, S. T., Davies, H. A., Mannan, S., Brunt, H., & Williams, R. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006165.pub3 · Cited by 105
Salvo, F., Moore, N. D., Arnaud, M., Robinson, P., Raschi, E., Ponti, F. D., Bégaud, B., & Pariente, A. (2016) · BMJ · doi:10.1136/bmj.i2231 · Cited by 101
Schernthaner, G., Barnett, A. H., Emser, A., Patel, S., Troost, J., Woerle, H. J., & von Eynatten, M. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01565.x · Cited by 96
“Previous meta-analyses of DPP-4 inhibitors found sitagliptin therapy to be associated with a slightly increased risk of overall and specific infections (nasopharyngitis, upper respiratory tract infection, urinary tract infection) [42,43].”
ResultPfützner, A., Schöndorf, T., Markolf Hanefeld, E., & Forst, T. M. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400326 · Cited by 92
DPP-4 inhibitors: What may be the clinical differentiators?
Gerich, J. E. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.07.006 · Cited by 93
“[47] Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL.”
Ashraf, A., Mudgil, P., Palakkott, A. R., Iratni, R., Gan, C., Maqsood, S., & Ayoub, M. A. (2020) · Journal of Dairy Science · doi:10.3168/jds.2020-18627 · Cited by 89
Sulphonylurea monotherapy for patients with type 2 diabetes mellitus
Hemmingsen, B., Schroll, J. B., Lund, S. S., Wetterslev, J., Gluud, C. N., Vaag, A. A., Sonne, D. P., Lundstrøm, L. H., & Almdal, T. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009008.pub2 · Cited by 89
RetractedCardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors: From Risk Factors to Clinical Outcomes
Scheen, A. J. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.05.2659 · Cited by 81
Derosa, G., & Maffioli, P. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.04.012 · Cited by 76
Dissecting the interaction between COVID‐19 and diabetes mellitus
Chee, Y. J., Tan, S. K., & Yeoh, E. C. K. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13326 · Cited by 82
Best Practice for Diabetic Patients on Hemodialysis 2012
Nakao, T., Inaba, M., Abe, M., Kaizu, K., Shima, K., Babazono, T., Tomo, T., Hirakata, H., Akizawa, T., & Japanese Society for Dialysis Therapy (2015) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.12299 · Cited by 75
DPP‐4 inhibitors and risk of infections: a meta‐analysis of randomized controlled trials
Yang, W., Cai, X., Han, X., & Ji, L. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2723 · Cited by 73
Zhong, J., Gong, Q., Goud, A., Srinivasamaharaj, S., & Rajagopalan, S. (2015) · Journal of Diabetes Research · doi:10.1155/2015/606031 · Cited by 74
“Several metaanalysis reports indicate an increased risk of infection such as nasopharyngitis and urinary tract infection in patients on DPP4i [156, 157].”
BackgroundCroxtall, J. D., & Keam, S. J. (2008) · Drugs · doi:10.2165/0003495-200868160-00009 · Cited by 68
Monami, M., Cremasco, F., Lamanna, C., Marchionni, N., & Mannucci, E. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1184 · Cited by 67
“The modest difference in endpoint BMI between DPP-4 inhibitors and placebo, which had been described previously [45], can be easily explained by the improvement of metabolic control and the consequent reduction of glycosuria.”
BackgroundLiraglutide Effect and Action in Diabetes (LEAD™) trial
Madsbad, S. (2009) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.4.2.119 · Cited by 70
Dipeptidyl peptidase-4 and kidney fibrosis in diabetes
Shi, S., Koya, D., & Kanasaki, K. (2016) · Fibrogenesis & Tissue Repair · doi:10.1186/s13069-016-0038-0 · Cited by 68
“Furthermore, DPP-4 inhibitors not only have benefits for patients who have recently developed diabetes [42] but also in patients with long-standing diabetes [43].”
BackgroundKhalil, R. M., Shata, A., El-Kader, E. M. A., Sharaf, H., Abdo, W. S., Amin, N. A., & Saber, S. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.115246 · Cited by 67
Cefalu, W. T., Buse, J. B., Prato, S. D., Home, P., LeRoith, D., Nauck, M. A., Raz, I., Rosenstock, J., & Riddle, M. C. (2014) · Diabetes Care · doi:10.2337/dc14-1395 · Cited by 62
Bloomfield, H. E., Greer, N. L., Newman, D. R., MacDonald, R. H., Carlyle, M. H., FITZGERALD, P. J., Rutks, I. R., & Wilt, T. J. (2012) · Cited by 59
Sarashina, A., Sesoko, S., Nakashima, M., Hayashi, N., Taniguchi, A., Horie, Y., Graefe-Mody, E. U., Woerle, H., & Dugi, K. A. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.06.004 · Cited by 58
Huang, J., Jia, Y., Sun, S., & Meng, L. (2020) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-020-00447-w · Cited by 59
“Meta-analyses suggested an increased risk for all-cause infections [34, 35].”
BackgroundCardiometabolic effects of a new class of antidiabetic agents
Desouza, C. V., Gupta, N., & Patel, A. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.02.016 · Cited by 54
Incretin agents in type 2 diabetes.
Ross, S. A., & Ékoé, J.-M. (2010) · PubMed · Cited by 50
Repurposing Drugs to Target the Diabetes Epidemic
Turner, N. A., Zeng, X., Osborne, B., Rogers, S., & Ye, J.-M. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.01.007 · Cited by 59
“Both classes of agent, however, have also been linked with various side effects in certain individuals [19,20].”
Huijben, J. A., Kramer, A., Kerschbaum, J., Meester, J. D., Collart, F., Arévalo, O. L. R., Helve, J., Lassalle, M., Pálsson, R., ten Dam, M. A. G. J., et al. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac165 · Cited by 53
Štulc, T., & Šedo, A. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.02.017 · Cited by 53
Yang, S. J., Min, K. W., Gupta, S. K., Park, J. Y., Shivane, V. K., Pitale, S., Agarwal, P. K., Sosale, A., Gandhi, P., Dharmalingam, M., et al. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12042 · Cited by 52
Gorricho, J., Garjón, J., Alonso, Á., Celaya, M. C., Saiz, L. C., Erviti, J., & López, A. B. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13288 · Cited by 51
Lee, S., Lee, H., Kim, Y., & Kim, E. Y. (2019) · Scientific Reports · doi:10.1038/s41598-019-49803-9 · Cited by 51
Cai, L., Cai, Y., Lu, Z., Zhang, Y., & Liu, P. (2011) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2011.01323.x · Cited by 51
Vora, K. A., Porter, G., Peng, R., Cui, Y., Pryor, K. D., Eiermann, G. J., & Zaller, D. M. (2009) · BMC Immunology · doi:10.1186/1471-2172-10-19 · Cited by 50
“A concern regarding the potential for DPP-IV inhibitors to affect immune function and increase infection rates has been raised [4,5], although a recently published analysis of safety using pooled source data showed no significant difference in the incidence of overall or specific types of infection [6].”
Lee, J.-G., Kang, D. G., Yu, J. R., Kim, Y. R., Kim, J. S., Koh, G. P., & Lee, D. H. (2011) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2011.35.2.149 · Cited by 48
“, nasopharyngitis and urinary tract infection), so further experimental and clinical studies are needed to determine the effects of DPP-4 on immune cell function [11-13].”
Clinical Pharmacology of Incretin Therapies for Type 2 Diabetes Mellitus: Implications for Treatment
Neumiller, J. J. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.04.024 · Cited by 47
Horie, Y., Kanada, S., Watada, H., Sarashina, A., Taniguchi, A., Hayashi, N., Graefe-Mody, E. U., Woerle, H., & Dugi, K. A. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.06.005 · Cited by 45
Naringin enhances reverse cholesterol transport in high fat/low streptozocin induced diabetic rats
Rotimi, S. O., Adelani, I. B., Bankole, E., & Rotimi, O. A. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.02.116 · Cited by 46
“Interestingly, current pharmacotherapies of T2DM now focus on inhibiting DPP-IV and enhancing insulin availability and sensitivity of tissues to insulin [29,30].”
BackgroundGliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis
Scheen, A. J. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.793671 · Cited by 43
“In a Cochrane review published in 2008 pooling 25 studies of good quality (11 trials with sitagliptin and 14 trials with vildagliptin), pancreatitis was not mentioned as being a concern with DPP-4 inhibitors [23].”
Signorovitch, J., Wu, E. Q., Swallow, E., Kantor, E., Fan, L., & Gruenberger, J.-B. (2011) · Clinical Drug Investigation · doi:10.2165/11592490-000000000-00000 · Cited by 44
DPP-4 Inhibitors in Clinical Practice
Palalau, A. I., Tahrani, A. A., Piya, M. K., & Barnett, A. H. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.11.2079 · Cited by 44
Gibbs, J. P., Fredrickson, J. O., Barbee, T., Correa, I., Smith, B. P., Lin, S., & Gibbs, M. A. (2012) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011420153 · Cited by 42
“1494 • J Clin Pharmacol 2012;52:1494-1505 T 2 diabetes mellitus (T2DM) is characterized by the progressive loss of pancreatic β-cell function and insulin resistance, leading to increased risk of cardiovascular disease and microvascular disorders such as retinopathy and nephropathy.(1,2) An increase in the understandin…”
BackgroundMethodInfluentialAlvarez, C., Lingvay, I., Vuylsteke, V., Koffarnus, R. L., & McGuire, D. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.143 · Cited by 42
“The effects on weight of the DPP-4 inhibitors were assessed in a Cochrane review of 25 studies evaluating sitagliptin and vildagliptin.(35) These drugs did not produce any significant changes in weight in the overall analysis; however, when limited to only placebo controlled trials, sitagliptin was associated with a 0.”
MethodIncretin-based therapies in the treatment of type 2 diabetes — More than meets the eye?
Łabuzek, K., Kozłowski, M., Szkudłapski, D., Sikorska, P., Kozłowska-Geller, M. A., & Okopień, B. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.01.009 · Cited by 42
“As far as DPP-4 inhibitors are concerned early studies indicated that there could be a connection between treatment with sitagliptin and increased incidence rate of infections (nasopharyngitis and urinary tract infections) and headache, especially with vildagliptin [79,80].”
BackgroundPattzi, H. M. R., Pitale, S., Salazar, M. A., Bennett, C., O'Farrell, A. M., Li, J., Cherrington, J. M., Guler, H. P., & PHX1149‐PROT202 Study Group (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01195.x · Cited by 41
Dobs, A. S., Goldstein, B. J., Aschner, P. J., Horton, E. S., Umpierrez, G. E., DURAN, L., HILL, J. S., Chen, Y., Golm, G. T., Langdon, R. B., et al. (2012) · Journal of Diabetes · doi:10.1111/j.1753-0407.2012.00223.x · Cited by 41
“Prior metaanalyses have reported small increases in risk of nasopharyngitis, urinary tract infection, and all-cause infection in patients treated with DPP-4 inhibitors.(30,31) However, in a subsequent pooled analysis that compared sitagliptin-treated and non-exposed patients in a larger sample, no significant differen…”
ResultElgendy, I. Y., Mahmoud, A. N., Barakat, A. F., Elgendy, A. Y., Saad, M. S., Abu‐Zaid, A., Wayangankar, S. A., & Bavry, A. A. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0208-x · Cited by 41
Pharmacological management of obesity an endocrine society clinical practice guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · Reproductive Endocrinology · doi:10.18370/2309-4117.2015.23.59-63 · Cited by 42
Low DPP4 expression and activity in multiple sclerosis
Tejera‐Alhambra, M., Casrouge, A., de Andrés, C., Ramos‐Medina, R., Alonso, B., Vega, J., Albert, M. L., & Sánchez‐Ramón, S. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.11.011 · Cited by 40
“DPP4−/− mice show increased levels of the intact insulinotropic forms of GLP-1 and GIP, accounting for the use of DPP4 inhibitors in the management of type 2 diabetes [52].”
BackgroundThe safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes
Russell-Jones, D. L. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02465.x · Cited by 40
Metadata
- Authors
- Richter, B., Bandeira-Echtler, E., Bergerhoff, K., & Lerch, C.
- Affiliations
- Düsseldorf University Hospital (DE)
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2008-04-23
- Volume
- 2010
- Issue
- 1
- Pages
- CD006739-CD006739
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- PMC
- PMC8985075
- OpenAlex
- W1916480346
- Cited by
- 308
- References
- 121
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 6 · 2023: 5 · 2022: 9 · 2021: 7 · 2020: 15 · 2019: 13 · 2018: 9 · 2017: 9 · 2016: 16 · 2015: 27 · 2014: 18 · 2013: 33 · 2012: 30
- FWCI
- 4.84
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cochrane Database of Systematic Reviews (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
- Keywords
- type 2 diabetes, sitagliptin, vildagliptin, glycemic control, HbA1c, beta-cell function, weight change, hypoglycemia, infection, drug safety, oral antidiabetic drugs, GLP-1 receptor agonists, treatment costs, health-related quality of life
- MeSH terms
- Sitagliptin Phosphate, Vildagliptin, Adamantane, Diabetes Mellitus, Type 2, Humans, Nitriles, Pyrazines, Pyrrolidines, Triazoles, Randomized Controlled Trials as Topic, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
